July 24, 2014 7:37 AM ET


Company Overview of bioCSL Inc.

Company Overview

bioCSL Inc. manufactures and supplies flu vaccines. The company offers AFLURIA, an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. It provides flu vaccine to Australia, New Zealand, and various countries in Europe, South America, and Asia. The company’s products are available through a network of distributors. bioCSL Inc. was formerly known as CSL Biotherapies, Inc. and changed its name to bioCSL Inc. The company was founded in 1968 and is based in King of Prussia, Pennsylvania. bioCSL Inc. operates as a subsidiary of CSL Ltd.

1020 First Avenue

King of Prussia, PA 19406

United States

Founded in 1968





Key Executives for bioCSL Inc.

Chief Executive Officer
Age: 57
Chief Financial Officer
Age: 51
Director and President of CSL Behring
Age: 65
Executive Vice President
Age: 57
Company Secretary
Age: 48
Compensation as of Fiscal Year 2014.

bioCSL Inc. Key Developments

CSL Biotherapies Inc. has Changed its Name to bioCSL Inc

On February 21, 2014, CSL Biotherapies Inc. changed its name to bioCSL Inc.

Sanofi Pasteur Inc, CSL Biotherapies, Inc., Novartis Vaccines and Diagnostics Inc and Glaxosmithkline LLC Wins $146.57 Million Federal Contract

Sanofi Pasteur Inc. announced that it won a share of a federal contract valued at up to $146,574,853.20 from the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention, Atlanta, for adult flu vaccine 2014-2015. CSL Biotherapies Inc., Novartis Vaccines and Diagnostics Inc. and Glaxosmithkline LLC shared in the award amount.

CSL Biotherapies, Inc. Wins US Government Contract for Influenza Pandemic Preparedness and Response

CSL Biotherapies, Inc. announced it has been awarded a contract by the United States Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile. Under the terms of the contract, the U.S. Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential. The company may also be called upon to develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen. Funding for the CSL Biotherapies contract is provided solely by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract. The contract has a maximum potential value of $1,511,407,737.78 if all optional activities are exercised over the duration of the contract.

Similar Private Companies By Industry

Company Name Region
Acylin Therapeutics, Inc. United States
Warner Chilcott Company, Inc. United States
Adheron Therapeutics, Inc. United States
Xellia Pharmaceuticals, Inc. United States
Pathogenics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact bioCSL Inc., please visit www.cslbiotherapies-us.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.